Unity Biotechnology Inc - Asset Resilience Ratio
Unity Biotechnology Inc (UBX) has an Asset Resilience Ratio of 29.44% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Unity Biotechnology Inc's Asset Resilience Ratio has changed over time. Check Unity Biotechnology Inc strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Unity Biotechnology Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see UBX market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $8.93 Million | 29.44% |
| Total Liquid Assets | $8.93 Million | 29.44% |
Asset Resilience Insights
- Very High Liquidity: Unity Biotechnology Inc maintains exceptional liquid asset reserves at 29.44% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Unity Biotechnology Inc Industry Peers by Asset Resilience Ratio
Compare Unity Biotechnology Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.11% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068 |
Biotechnology | 20.87% |
Annual Asset Resilience Ratio for Unity Biotechnology Inc (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Unity Biotechnology Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 41.55% | $15.65 Million | $37.66 Million | +5.94pp |
| 2023-12-31 | 35.62% | $23.40 Million | $65.69 Million | -30.37pp |
| 2022-12-31 | 65.99% | $82.06 Million | $124.35 Million | +21.75pp |
| 2021-12-31 | 44.24% | $55.17 Million | $124.71 Million | -6.87pp |
| 2020-12-31 | 51.11% | $79.89 Million | $156.32 Million | -8.42pp |
| 2019-12-31 | 59.53% | $90.02 Million | $151.22 Million | -26.34pp |
| 2018-12-31 | 85.86% | $155.74 Million | $181.38 Million | +8.22pp |
| 2017-12-31 | 77.64% | $79.21 Million | $102.02 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $96.65 Million | -- |
About Unity Biotechnology Inc
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. Its lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. The company also develop… Read more